The Limits That Caribou Biosciences Is Pushing
CRISPR engineering of the meditated genome was a development so revolutionary that it allowed all scientists the ability to engineer human genome, any and all part of it. And it did it with the astonishing precision. This was a huge milestone for medical science, and it was the headlines of every newspaper – because this technology had such a great range of capability in treating various diseases considering genetic disorders, and mutations on the genes.
In the time when a founder of Caribou Biosciences, and that is Dr. Rachel Haurwitz, begun researching CRISPR, it was then just an immune system that is uncharacterized and prokaryotic. She decided to co-found her company when she recognized that it had the potential for the various range of use. Caribou Biosciences company can utilize the specific enzyme Cas9. Her company developed technologies and tools for cellular analysis and engineering. Their goal is to research and use the potential of this engineering to its full potential. How? By considering concerns about delivery in organisms and cells, by refining efficiency and improving specificity. This company is already making commercial partners.
The wonders of Cas9
This company has the technologies and research tools that are providing astonishing capabilities to applied and basic development and research in the industrial bioscience, agricultural biotechnology, drug development. The founder is sure there is a great opportunity in making custom models of the cell line, for specific diseases. The people in this company believe in the significant opportunities on the market in molecules production, improving crops and plants, gene therapy for humans…
Cas9 have the great capability in therapy in modifying the cells of patients at the level that is genomic, all for the purpose to repair the genes or prevent infections. The founder believes it will take science some time until it can achieve this rising potential because of the long timeline that is normal for this kind of projects. But she also believes that the trickiest part will not be editing the cells because there is a various technology that is doing that – the hard part will be safely and appropriately delivering this kind of technology. The one thing is sure, it is unbelievably exciting how fast this technology is adopted by researchers, and the expansion of its use and development will be a huge step for science.